Red blood cell transfusions have become standard of care for the prevention of life-threatening anemia in patients with b-thalassemia and sickle cell disease (SCD). However, frequent transfusions can lead to accumulation of iron that can result in liver cirrhosis, diabetes mellitus, arthritis, arrhythmias, cardiomyopathy, heart failure, and hypogonadotropic hypogonadism. Iron chelation therapy has been shown to reduce serum ferritin levels and liver iron content, but limitations of trial design have prevented any demonstration of improved survival. The objective of this systematic review was to investigate the impact of iron chelation therapy on overall and event-free survival in patients with b-thalassemia and SCD. Eighteen articles discussing survival in b-thalassemia and 3 in SCD were identified. Overall iron chelation therapy resulted in better overall survival, especially if it is instituted early and compliance is maintained. Comparative studies did not show any significant differences between available iron chelation agents, although there is evidence that deferiprone is better tolerated than deferoxamine and that compliance is more readily maintained with the newer oral drugs, deferiprone and deferasirox. Iron chelation therapy, particularly the second-generation oral agents, appears to be associated with improved overall and eventfree survival in transfusion-dependent patients with b-thalassemia and patients with SCD. exceeded. 2 In turn, the presence of NTBI results in iron deposits in the cells of various organs (including liver, heart, pancreas, endocrine glands, and joints) and the formation of reactive oxygen species. [4] [5] [6] Ultimately, this can lead to symptoms associated with damage to involved organs, such as liver cirrhosis and hepatocellular carcinoma, diabetes mellitus, arthritis, arrhythmias, heart failure, and hypogonadotropic hypogonadism.
Searches of these databases were performed using terms such as "sickle cell disease," "b-thalassemia," and/or shortened terms such as "SCD" or "thalassemia"; other search terms included iron chelation, iron overload, survival, death, study, and trial. Searches of PubMed employed filters for comparative study, evaluation study, multicenter study, observational study, and randomized clinical trials, where possible.
| Abstract review
Two of the authors (Dr. Ballas and Dr. Zeidan) independently reviewed the abstracts identified by the literature search. In cases where the reviewers could not determine from the abstract alone whether an article met the eligibility criteria, a full-text copy of the article was retrieved for review. The reviewers were not masked as to author or journal name. References were excluded from the systematic review based on the following criteria: lack of evidence for survival analysis comparison between regimens and inclusion of less than 25 patients in the study. Only those articles with unanimous support from the reviewers were included in the systematic review. Details of the included studies were then abstracted from each publication and collected for categorization. Results from these studies are summarized.
| RE S U L TS

| b-thalassemia
The electronic literature searches yielded a total of 459 relevant articles on b-thalassemia that met our search criteria. After a review of the study abstracts, 43 were deemed appropriate for full-text review. reporting survival data (n 5 6), not reporting comparative data (n 5 6), not reporting on iron overload or chelation therapy (n 5 4), having less than 25 subjects (n 5 2), focusing on patients who underwent hematopoietic stem cell transplant (n 5 6), and, in 1 case, a duplicate article reporting the same data.
| Study characteristics
A total of 18 individual papers describing 15 different studies were published between 2000 and 2017, and are summarized in Table   1 . 10, [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] These studies included 7189 patients; however, some patients likely were counted more than once since the multicenter studies from Borgna-Pignatti et al., although distinct, drew on the same patient populations in Italy. 16, 17 A number of other multicenter studies were also conducted in Italy, and may also have included some of these same patients. 10, [18] [19] [20] [21] Only 2 of the 15 studies were randomized controlled trials, 10, 20 with the remainder being retrospective and/or longitudinal studies.
Only 1 of the retrospective/longitudinal studies compared survival outcomes in b-thalassemia patients according to the ICT received 17 ; a second study compared monotherapy to combination therapy. 22 The remaining studies investigated survival outcomes according to various baseline and treatment characteristics: 1 investigated factors associated with death in a case-control study 18 ; 4 studied outcomes according to compliance with or duration of ICT 18, [23] [24] [25] ; 4 compared survival outcomes according to period of treatment (i.e., before or after availability of different iron chelation treatments) 16, 22, 26, 27 ; 1 measured survival in patients with thalassemia major and thalassemia intermedia before and after introduction of deferoxamine 21 ; and 1 measured rates of death in hepatitis C virus (HCV)-infected and noninfected patients receiving ICT with deferoxamine. 25 
| Clinical outcomes associated with ICT
A number of studies compared the efficacy of deferiprone and deferoxamine. 10, 17, 32 One of the 2 randomized controlled trials compared the efficacy of deferiprone and deferoxamine in patients with b-thalassemia intermedia and iron overload. 10 There was no significant difference in survival over the course of the 5-year study between deferiprone and deferoxamine (P 5 .36). In addition, there was no significant difference in mean serum ferritin levels (P 5 .26), the percentage of patients with serum ferritin levels 400 mg/mL, or in the proportion of patients who switched therapy. Agranuloyctosis was reported in 4 patients in the deferiprone group versus none in the deferoxamine group (P 5 .118). In addition, neutropenia occurred in 6 patients and 0 patients in the deferiprone and deferoxamine groups, respectively (P 5 .027). However, overall, deferiprone was better tolerated than deferoxamine, with no treatment withdrawals due to adverse events in the deferiprone group compared with 8 in the deferoxamine group (P 5 .002).
A single-center retrospective analysis of 129 b-thalassemia patients with at least 4 years' treatment history with deferiprone or deferoxamine compared overall survival and cardiac disease-free survival with the 2 agents. 32 Overall, 0/54 patients who received deferiprone and 4/75 patients who received deferoxamine died during the study period; 3 of these patients died of cardiac disease. Cardiac disease-free survival favored those treated with deferiprone (P 5 .003).
At the start of the study, 7 patients in the deferiprone group and 12 in the deferoxamine group had evidence of cardiac dysfunction, but over the course of the study only 2 patients (4%) in the deferiprone group compared with 13 (21%) in the deferoxamine group developed new cardiac disease. The final study that compared outcomes with deferiprone and deferoxamine was a retrospective longitudinal study that reported survival in patients with b-thalassemia major who received deferoxamine compared with those who had switched to deferiprone during the study period. 17 The rate of death among those who switched to deferiprone was remarkably lower (1.3%) than that among those who continued to take deferoxamine (6.7%); however, given the small number of patients involved, this difference was not statistically significant (P 5 .19). Only 6/157 patients discontinued deferiprone; however, reasons for discontinuation of or switch from deferoxamine were not given, so it is not possible to estimate the relative compliance with the 2 agents. Of 26 patients who died, 24 were in the deferoxamine group and 2 were in the deferiprone group; 15 deaths in the deferoxamine group were cardiac related versus 0 in the deferiprone group.
The other randomized controlled trial compared sequential treatment of b-thalassemia major subjects with deferiprone for 4 days/ week and deferoxamine for the remaining 3 days/week to deferiprone alone 7 days/week. 20 There was no significant difference in survival between the alternating and monotherapy arms (P 5 .32). The sequential deferiprone/deferoxamine group did, however, demonstrate a linear reduction in ferritin levels during the 5-year study while there was no change in the deferiprone alone group. The 2 treatment approaches were similarly tolerated and had similar annual associated health care
costs of approximately e6000 per person/year. A follow-on study indicated that treatment with deferoxamine alone was a significant predictor of mortality compared with deferiprone alone, sequential deferiprone/deferoxamine, and combined deferiprone/deferoxamine, with a hazard ratio (HR) of 29.4 (95% confidence interval [CI]: 3.6, 240; P 5 .0016). 19 Other significant predictors of mortality included past heart failure (P 5 .0014), presence of arrhythmia (P < .000001), cirrhosis (P < .000001), diabetes (P 5 .0024), and hypothyroidism (P 5 .0012). A significant interaction was also found between age and sex, and was also observed with a HR of 1.03 (95% CI: 1.01, 1.05) for each additional year of age in males compared with females (P 5.013), possibly due to better compliance in females. 20 A second longitudinal study examined survival in patients with b-thalassemia major who received combination ICT with deferoxamine and deferiprone compared with those who received monotherapy only. 22 Combination ICT was found to have a statistically significant impact on the rate of death, with an HR of 0.14 per year of therapy (95% CI: 0.04, 0.41; P < .001). There was a high incidence of treatment discontinuation in this study (24.7%), with 5% of patients discontinuing because of agranulocytosis and 5.6% due to gastrointestinal disturbances. Finally, among patients with or without chronic HCV infection, there was no significant difference in overall survival (P 5 .524) or in regard to cardiac-related complications (P 5 .176). 25 In patients with HCV, the presence of malignancy other than hepatocellular carcinoma was a predictive factor for survival (P 5 .015), in addition to heart failure.
Both of the randomized controlled studies suggest that there is little difference in terms of survival, ferritin reduction, safety, and tolerability between the most commonly used iron chelation treatments. The 13 uncontrolled studies, however, suggest that deferiprone may be better tolerated; it is associated with better survival outcomes than deferoxamine.
Combination therapy may be associated with even better outcomes.
| Compliance with ICT
In a retrospective study of patients with transfusion-dependent b-thalassemia, mortality was significantly higher among patients who were less than 20% compliant than those with better compliance (P < .05).
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Noncompliance was most common among those taking deferoxamine compared with deferiprone and deferasirox. A logistic regression analysis of a case-control study in which cases were patients who had died and controls were patients who were living similarly found that good compliance was a significant protective risk factor for survival (odds ratio [OR] 5 7.33; 95% CI: 2.76, 19.48; P 5 .001). 18 Younger age at first chelation and treatment with deferiprone were also significant protective risk factors. In the study of patients with or without HCV, nonadherence to chelation treatment was found to be a negative predictive factor of survival (HR, 0.234; 95% CI: 0.075, 0.732; P 5 .013). 25 Another retrospective study of patients with b-thalassemia major in
Iran showed that a longer duration of treatment with deferoxamine resulted in significantly longer overall survival. 24 This study is difficult to interpret, however, as little additional information regarding characteristics that predicted survival is provided. At some point, longer treatment duration is a function of survival, so perhaps demonstrating that longer treatment duration correlates with improved survival is merely demonstrating the obvious.
| Era of treatment
Advances in the treatment of b-thalassemia over time have been documented in longitudinal studies. A study from Italy comprising more than 1000 patients from 7 centers demonstrated that individuals born after 1970 experienced substantial improvements in survival compared with those born earlier, most likely due to the introduction of ICT. 16 Although, historically, measurement of hepatic iron stores was regarded as the best marker of body iron burden, 9 in this Italian study, lower serum ferritin levels predicted longer survival and a reduced risk of cardiac complications and hypogonadism. 16 A similar longitudinal analysis conducted in Cyprus found that patients with thalassemia major who were born after 1973 had significantly better survival than those born earlier (HR 5 0.14; 95% CI: 0.04, 0.41; P < .001).
22
A more recent study reported survival outcomes before and after introduction of deferiprone. 28 During the period 1990-1999, when the only available iron chelation treatment was deferoxamine, the standardized mortality ratio among 20-to 39-year-old patients was 28. 27 Although the study notes that the true impact of specific ICT on outcomes could not be evaluated because of the switching of agents due to side effects and the patient condition, the incidence of death decreased from 2.9% in 2007 to 0.7% in 2011. cardiac disease-free survival demonstrated a statistically significant difference among the 3 cohorts (P 5 .027 and P 5 .004, respectively). The study also demonstrated a significant survival benefit for patients with serum ferritin levels 3000 ng/mL compared with those who had serum ferritin levels >3000 ng/mL (P 5 .006).
A study published in 2008 found a steady improvement in life expectancy from 17 years in 1970 to 37 years in 1990. 30 Life expectancy since 2000 was found to be more than 40 years in over 80% of patients. Although much of this improvement occurred concurrent with the introduction of iron chelation treatments, the authors attributed at least some of this increase in life expectancy to the introduction of T2* cardiovascular magnetic resonance that has allowed cardiac siderosis to be more readily diagnosed and managed.
| Sickle cell disease
The electronic literature analyzes yielded a total of 231 articles concerning SCD, of which 6 were selected for full-text review ( Figure 2 ).
As with b-thalassemia, these numbers could potentially have included studies reported in multiple articles. After review, 3 articles were excluded and 3 were included in the systematic review. Reasons for exclusion included small patient numbers, being theoretical (modeling results of hypothetical patients), and having no comparator arm.
| Study characteristics
The 3 selected studies were published between 2001 and 2014 ( Table   2 ) and included 294 patients with characteristics relevant to the study. [33] [34] [35] Only 1 of the 3 studies was designed to compare outcomes of ICT, a 5-year randomized controlled trial comparing deferiprone and deferoxamine. 33 The other 2 studies were observational, longitudinal, natural history studies, neither of which formally investigated ICT.
| Clinical outcomes associated with iron overload
Although not a study of ICT per se, the study by Ballas et al. demonstrated the importance of iron overload in SCD. 35 Mortality among patients with ferritin levels >1500 ng/mL and transferrin saturation >50% was 64% compared with 5% of those who had ferritin levels <100 ng/mL and transferrin saturation <50%. Similarly, organ failure occurred in 71% with iron overload compared with only 19% without.
In addition, 3 pain episodes per year occurred in 64% and 38% in those with and without iron overload, respectively. The study by Fung et al. was a longitudinal study in chronically transfused subjects. 34 Of those with SCD who received transfusions, 70.7% also underwent ICT.
Transfused subjects who died initiated ICT significantly later in life vs.
those who survived (26.8 years vs. 14.2 years, P 5 .01).
Both the study from Ballas et al. 35 and the one from Fung et al. 34 are limited in that neither was controlled; in neither case were patient and disease characteristics provided for those in the higher-risk group relative to the lower-risk group. However, Fung et al. did note that there was no significant difference in serum ferritin levels or liver iron concentration between those who died and those who survived. 34 Therefore, it is not evident that iron overload or chelation treatment the SCD population receiving ICT was a particularly fragile group with higher rates of hospitalization and mortality, but that these rates may not necessarily be attributable to iron overload, with increased ferritin levels merely reflecting a greater number of transfusions in sicker patients. 34 The only randomized controlled study evaluating ICT compared deferiprone and deferoxamine. 33 Over the course of the 5-year study, both agents substantially reduced serum ferritin levels, with the number of patients with serum ferritin levels <400 ng/mL being significantly higher in the deferiprone group compared with the deferoxamine group (36.6% vs. 3.3%; P 5 .002). However, KaplanMeier survival probability curves showed no significant difference in survival between the 2 groups over 5 years (P 5 .38). Six patients died during the trial, 4 in the deferoxamine group and 2 in the deferiprone group. The cause of death in each case was not related to iron overload or chelation therapy, but was consistent with the natural history of SCD. This study thus demonstrated that ICT can significantly reduce serum ferritin levels and is associated with good overall survival, but the lack of a placebo comparator limited the conclusions that could be made about the impact of this approach on patient survival.
| D I SCUSSION
The more recently approved ICTs deferiprone and deferasirox have been approved based on surrogate markers such as liver iron content and serum ferritin levels, relative to deferoxamine, which was approved by the US Food and Drug Administration in 1968. 11, 12 As a result, this ICTs. 10, 20, 33 As with the earlier randomized trial of ICT, the failure to observe differences between deferoxamine and newer treatment approaches in these trials in terms of outcomes and tolerability is likely, at least in part, due to the small size of the trials. However, uncontrolled studies suggest that deferiprone may be better tolerated and may be associated with better outcomes than deferoxamine. The only study to date suggesting a survival benefit for deferasirox versus deferiprone was a retrospective analysis, which showed improved survival in
Taiwan after the introduction of deferasirox.
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A prospective study of survival outcomes with ICT is logistically difficult due to the long duration of study required. Comparative randomized controlled trials with sufficient power to differentiate outcomes between different ICTs are even more difficult than placebocontrolled trials as they require enrollment of even more patients. The availability of eligible patients for these trials further complicates their design. Furthermore, given the importance of treatment adherence discussed here, whichever treatment an individual patient can administer regularly is likely to be a more important factor to that individual than which agent demonstrates superiority in a head-to-head clinical trial. In addition, complications due to iron overload are rare before the second decade of life. 3, 24 However, the average interval between the first appearance of cardiac complications and death in patients with b-thalassemia ranges from 1 to 2.7 years, depending on the degree of vigilance in screening for heart problems. 24 The randomized controlled trial by Calvaruso et al. studied only patients with non-transfusiondependent b-thalassemia intermedia, a condition that requires only intermittent blood transfusions. 10, 36 As a result, the risk of death in these patients is somewhat lower than with patients with b-thalassemia major, further reducing the probability of observing significant differences between iron chelation treatments.
Most of the data on the effectiveness of ICT comes from longitudinal studies. These studies have demonstrated that treatment outcomes have improved significantly over time with the progressive introduction of new and improved ICTs, including oral treatments and combination therapy. 16, 19, 20, [22] [23] [24] [25] [26] [27] [28] [29] [30] 36 The effectiveness of iron chelation has also been demonstrated in studies investigating treatment compliance where survival is much better in patients with good compliance with ICT. 18, [23] [24] [25] Importantly, compliance has been much improved by the introduction of oral agents such as deferiprone and deferasirox. 23 Compliance with deferoxamine, which requires daily subcutaneous infusions, is difficult and has been associated with worse overall survival.
| C ONC LUSI ON S
The lack of randomized controlled trials of ICT makes it difficult to draw conclusions and make recommendations about how best to apply 
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